Passage Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
March 03, 2022 07:00 ET
|
Passage Bio
Presented positive interim biomarker, safety and efficacy data, including gains in developmental milestones, for Cohort 1 patients in Imagine-1 clinical trial for GM1 gangliosidosisDosed first...
Passage Bio to Participate in Upcoming March Investor Conferences
March 01, 2022 07:00 ET
|
Passage Bio
PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
Passage Bio to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022
February 24, 2022 07:00 ET
|
Passage Bio
PHILADELPHIA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium
February 11, 2022 11:00 ET
|
Passage Bio
Both children with late infantile GM1 gangliosidosis in Cohort 1 of the Imagine-1 clinical trial showed developmental improvement in assessments by study investigators and caregiversInterim safety...
Passage Bio to Showcase GM1 Gangliosidosis and Krabbe Clinical Programs at 2022 WORLDSymposium, February 7 – 11
January 31, 2022 07:00 ET
|
Passage Bio
Late-breaker presentation to include new clinical data from Cohort 1 in the Imagine-1 clinical trial for GM1 gangliosidosis, Friday, February 11Podium presentations on clinical trial designs for...
Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline
January 10, 2022 07:00 ET
|
Passage Bio
Present longer follow-up and clinical milestones for Cohort 1 of the Imagine-1 GM1 gangliosidosis clinical trial at the 18th Annual WORLDSymposium, February 11, 2022Dose first patients in Cohorts 2...
Passage Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022 07:00 ET
|
Passage Bio
PHILADELPHIA, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis
December 17, 2021 07:00 ET
|
Passage Bio
– Independent Data Monitoring Committee recommends proceeding with two additional planned patient cohorts, which are now being recruited in parallel – Positive safety profile, including no serious...
Passage Bio Announces Pipeline Expansion and Clinical Program Update
December 08, 2021 07:00 ET
|
Passage Bio
Exercised two additional options with University of Pennsylvania’s Gene Therapy Program aligned with company’s focus on CNS diseases with high unmet need Huntington’s disease, a fatal rare adult...
Passage Bio Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
November 19, 2021 16:00 ET
|
Passage Bio
PHILADELPHIA, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...